Krystal Biotech, Inc. KRYS Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s operating lease liabilities?
- Krystal Biotech, Inc. (KRYS) reported operating lease liabilities of $7.31M in Q1 2026.
- How has Krystal Biotech, Inc.'s operating lease liabilities changed year-over-year?
- Krystal Biotech, Inc.'s operating lease liabilities decreased by 11.9% year-over-year, from $8.3M to $7.31M.
- What is the long-term trend for Krystal Biotech, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s operating lease liabilities has grown at a 18.0% compound annual growth rate (CAGR), from $3.31M to $7.57M.
- What does operating lease liabilities mean?
- The total amount of rent or lease payments due after the next year.
- How do you interpret operating lease liabilities?
- An increase indicates a long-term expansion of the company's physical infrastructure, while a decrease suggests lease expirations or a reduction in long-term commitments.
- How does operating lease liabilities compare across companies?
- Standard for companies with significant physical infrastructure; comparable across firms following modern lease accounting standards.